Waverly Advisors’s Trinity Biotech TRIB Stock Holding History

Waverly Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-248	Closed	-$24K	–	397
2015 Q1	$24K	Hold	248	–	–	0.01%	182
2014 Q4	$22K	Hold	248	–	–	0.01%	208
2014 Q3	$23K	Hold	248	–	–	0.01%	320
2014 Q2	$29K	Buy	+248	New	+$29.4K	0.01%	290

Other funds holding TRIB

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

CAM

Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Waverly Advisors's TRIB Position: Q2 2015 in Review

Waverly Advisors sold out of Trinity Biotech (TRIB) in Q2 2015, closing a stake of 248 shares — an estimated $24K sold.

Waverly Advisors first reported a position in TRIB in Q2 2014 and held it in 4 quarters. The position peaked at $29K in Q2 2014. 92 funds tracked by Wall St. Rank hold TRIB as of Q2 2015.

Waverly Advisors reported no remaining Trinity Biotech position as of Q2 2015 after selling out during the quarter.
Waverly Advisors sold 248 Trinity Biotech shares in Q2 2015, an estimated $24K.
Waverly Advisors first reported a position in Trinity Biotech in Q2 2014 and held it in 4 quarters.
Waverly Advisors's Trinity Biotech position peaked at $29K in Q2 2014.
92 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2015.

Based on Waverly Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.